ZEISS India introduces FCI Vitreoretinal surgical devices in India

Bangalore, 27th June 2019

ZEISS is pleased to introduce the FCI vitreoretinal range of high-performance surgical devices and instruments in India. The FCI products will be available through an exclusive partnership between ZEISS India and FCI (France Chirurgie Instrumentation) S.A.S. FCI, a ZEISS group company based in France, is a world leader in the development of a wide range of ophthalmic surgical devices.

To make the products more accessible to customers, ZEISS India has developed an exclusive online web-shop where surgeons can go and buy FCI products. The online web-shop www.zeissindiaonline.com provides 24/7 access where one can place order and make payment for the purchases. The web-shop enables regular updates on the progress of the shipment till it reaches the end-user.

The vitreoretinal line of devices and instruments are designed to provide retina surgeons with high performance products for vitreoretinal procedures. These includes wide selection of disposable laser probes, fiber optic probes and laser illumination sources that can connect to any manufacturers' vitreoretinal power source.

Other products in the vitreoretinal launch include:

  • Auto stable Trocar system - Retilock
  • Backflush for passive and active aspiration
  • Purified silicone oil and PFCL
  • ILM Forceps, Scissors and Tano polishers
  • Vitrectomy Lenses
  • Invitria – Intravitreal Injection Assistant
  • Scleral Buckles

FCI performs extensive research and development to provide surgeons with outstanding products that enhance the efficiency and effectiveness of vitreoretinal procedures. Since its inception in 1984, FCI has worked in close collaboration with leading ophthalmic surgeons worldwide to develop and test products that contribute to the quality of patients' lives and products that respond to surgeons' needs with advanced materials.

For more information on the FCI Vitreoretinal products please contact by calling 1-800-103-5264 (Toll-free) or by email at support .med .in @zeiss .com

Contacts for the press: 

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
E-mail: investors .meditec @zeiss .com


Brief profile Carl Zeiss Meditec AG:

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med